SCHEMBL2867923

SCHEMBL2867923

COc1cccc(Oc2cccc(C(=O)O)c2)c1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.73
CES2 O00748 1/20 0.65
CES1 P23141 1/20 0.65
MRGPRX4 Q96LA9 1/20 0.63
KMO O15229 1/20 0.61
PARP1 P09874 1/20 0.61
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
MITF O75030 1/20 0.60
PGR P06401 1/20 0.60
KDM4E B2RXH2 3/20 0.59
POLB P06746 2/20 0.59
ALDH1A1 P00352 1/20 0.59
CYP2C9 P11712 1/20 0.56
PPARG P37231 1/20 0.56
FABP1 P07148 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CYP2C8 P10632 1/20 0.55
KMT2A Q03164 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63427 0.93 CES2 (0.74) AKR1C3CES2CES1MRGPRX4PARP1
SCHEMBL29351426 0.93 CES2 (0.74) AKR1C3CES2CES1MRGPRX4PARP1
SCHEMBL6827745 0.93 CES2 (0.74) AKR1C3CES2CES1MRGPRX4PARP1
SCHEMBL9618429 0.92 KDM4E (0.70) AKR1C3CES2CES1MRGPRX4KMO
SCHEMBL2857877 0.91 AKR1C3 (0.77) AKR1C3CES2CES1MRGPRX4KMO
Hydrochloric Acid SCHEMBL5773812 0.91 CES2 (0.71) AKR1C3CES2CES1MRGPRX4PARP1
SCHEMBL1448094 0.91 CES2 (0.71) AKR1C3CES2CES1MRGPRX4PARP1
Hydrochloric Acid SCHEMBL30142542 0.91 CES2 (0.71) AKR1C3CES2CES1MRGPRX4PARP1
Water SCHEMBL27893543 0.91 CES2 (0.71) AKR1C3CES2CES1MRGPRX4PARP1
SCHEMBL10403563 0.91 CES2 (0.71) AKR1C3CES2CES1MRGPRX4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651888-B1 N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders UNIV LEUVEN KATH (BE) 2017-05-17 EP disclosed
CN-103261156-B For treating the noval chemical compound of neurodegenerative disease 鲁汶天主教大学研究开发部 2016-12-28 CN disclosed
US-9266832-B2 Compounds for the treatment of neurodegenerative diseases Katholieke Universiteit Levun (BE) 2016-02-23 US disclosed
CN-102083836-B Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers SENOMYX INC 2015-01-28 CN disclosed
US-20130295261-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. (US) 2013-11-07 US disclosed
EP-2651888-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-17 US disclosed
CN-103261156-A New compounds for the treatment of neurodegenerative diseases LEUVEN K U RES & DEV 2013-08-21 CN disclosed
US-8420145-B2 Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers SENOMYX, INC. (US) 2013-04-16 US disclosed
WO-2012080221-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed
EP-2254891-A2 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS Senomyx, Inc. (US) 2010-12-01 EP disclosed
WO-2009111447-A2 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. (US) 2009-09-11 WO disclosed
US-20090220662-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS SENOMYX, INC. 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 AKR1C3 1608/4885CES2 2945/4885CES1 3142/4885
US-20090220662-A1 ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS TAS2R10, TAS2R41, TAS2R30 AKR1C3 3307/4885CES2 2606/4885CES1 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.